Uridine Triphosphate

Summary

Uridine Triphosphate (CHEMBL336296) is a phase-3 clinical-stage small molecule targeting P2RY2, P2RY4, and P2RY6; indicated across 2 conditions including lung neoplasm and interstitial lung disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 4 (P2RY2, P2RY4, P2RY6…)
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 484.14 Da · C9H15N2O15P3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL336296
Name	Uridine Triphosphate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6133
ChEBI	CHEBI:15713
Molecular formula	C9H15N2O15P3
Molecular weight	484.14
InChIKey	PGAVKCOVUIYSFO-XVFCMESISA-N

SMILES: C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O

IUPAC name: [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

ChEBI definition: A pyrimidine ribonucleoside 5’-triphosphate having uracil as the nucleobase.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite, mouse metabolite.

Also known as: INS-316, INS316, Uridine 5’-triphosphate, Uridine triphosphate, Utp, Uridine-5’-triphosphate, Uridine triphosphate (UTP), UTP, uridine triphosphate, uridine 5’-triphosphate, SID26756678, URIDINE TRIPHOSPHATE

Parent form; salt/anhydrous children: CHEMBL5077459

Patent coverage: 7,183 distinct patent families (17,782 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
P2RY2	P2Y2 receptor	Full agonist	8.1	1%	P41231
P2RY4	P2Y4 receptor	Full agonist	6.3	0%	P51582
P2RY6	P2Y6 receptor	Partial agonist	5.2	3.2%	Q15077
P2RY11	P2Y11 receptor	Full agonist	5.2	0%	Q96G91

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, P2Y purinoceptor 2, Inositol monophosphatase 1, P2Y purinoceptor 4, P2Y purinoceptor 4, P2Y purinoceptor 2, P2Y purinoceptor 2, P2Y purinoceptor 6.

Bioactivity

ChEMBL activities: 62 potent at pChembl ≥ 5 of 65 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P2RY2	8.25	EC50	5.61	nM	CHEMBL_ACT_18092217
P2RY2	8.15	EC50	7	nM	CHEMBL_ACT_2011533
P2RY2	8.15	EC50	7	nM	CHEMBL_ACT_2013697
P2RY2	7.75	EC50	17.9	nM	CHEMBL_ACT_6163205
P2RY2	7.7	EC50	20	nM	CHEMBL_ACT_8045538
P2RY2	7.52	EC50	30	nM	CHEMBL_ACT_1104765
P2RY2	7.43	EC50	37.2	nM	CHEMBL_ACT_2513448
P2RY4	7.41	EC50	39	nM	CHEMBL_ACT_2011552
P2RY4	7.41	EC50	39	nM	CHEMBL_ACT_2013716
P2RY2	7.37	EC50	43	nM	CHEMBL_ACT_1782117
P2RY2	7.31	EC50	49	nM	CHEMBL_ACT_1820922
P2RY2	7.3	EC50	50.1	nM	CHEMBL_ACT_2513451
P2RY2	7.26	EC50	55	nM	CHEMBL_ACT_6214779
P2RY2	7.23	EC50	59	nM	CHEMBL_ACT_2513449
P2RY2	7.22	EC50	60	nM	CHEMBL_ACT_2350099
P2RY2	7.22	EC50	60	nM	CHEMBL_ACT_3309948
P2RY2	7.22	EC50	60	nM	CHEMBL_ACT_6214768
P2RY2	7.15	EC50	70.6	nM	CHEMBL_ACT_18092219
P2RY4	7.14	EC50	73	nM	CHEMBL_ACT_1820923
P2RY4	7.1	EC50	80	nM	CHEMBL_ACT_6214809
P2RY2	7.09	EC50	80.4	nM	CHEMBL_ACT_2513425
P2RY4	7.06	EC50	87	nM	CHEMBL_ACT_1782118
P2RY4	7.05	EC50	90	nM	CHEMBL_ACT_2350134
P2RY4	7.05	EC50	90	nM	CHEMBL_ACT_3309938
P2RY4	7.05	EC50	88.4	nM	CHEMBL_ACT_6163231
P2RY4	7.05	EC50	90	nM	CHEMBL_ACT_6214776
P2RY4	7	EC50	100	nM	CHEMBL_ACT_1104766
P2RY2	7	EC50	100	nM	CHEMBL_ACT_18488165
P2RY2	7	EC50	100	nM	CHEMBL_ACT_3105585
P2RY2	6.97	EC50	108	nM	CHEMBL_ACT_2513456
P2RY2	6.96	EC50	109.7	nM	CHEMBL_ACT_1998139
P2RY2	6.92	EC50	120	nM	CHEMBL_ACT_18488170
P2RY2	6.92	EC50	121	nM	CHEMBL_ACT_2513455
P2RY2	6.91	EC50	124	nM	CHEMBL_ACT_2513450
P41232	6.89	EC50	130	nM	CHEMBL_ACT_1690753
P2RY2	6.86	EC50	138	nM	CHEMBL_ACT_2513452
P2RY2	6.85	EC50	140	nM	CHEMBL_ACT_11011188
P2RY2	6.85	EC50	140	nM	CHEMBL_ACT_18488160
P2RY2	6.85	EC50	140	nM	CHEMBL_ACT_25089890
P2RY2	6.85	EC50	140	nM	CHEMBL_ACT_38857
P2RY2	6.8	EC50	160	nM	CHEMBL_ACT_18488167
P2RY2	6.8	EC50	157	nM	CHEMBL_ACT_2513454
P2RY6	6.37	EC50	424	nM	CHEMBL_ACT_2011557
P2RY2	6.35	EC50	450	nM	CHEMBL_ACT_1690754
P2RY4	6.32	EC50	480	nM	CHEMBL_ACT_2302276
P2RY4	6.32	EC50	480	nM	CHEMBL_ACT_8031839
P2RY4	6.3	EC50	500	nM	CHEMBL_ACT_3105588
P2RY4	6.26	EC50	550	nM	CHEMBL_ACT_25089895
P2RY2	6.19	EC50	640	nM	CHEMBL_ACT_2302275
P2RY2	6.19	EC50	640	nM	CHEMBL_ACT_8031821
P2RY2	6.11	EC50	781	nM	CHEMBL_ACT_2513556
P2RY4	6.05	EC50	900	nM	CHEMBL_ACT_11011189
P2RY2	6.04	EC50	911	nM	CHEMBL_ACT_18092221
P2RY2	6	EC50	996	nM	CHEMBL_ACT_18092224
P2RY2	5.9	EC50	1250	nM	CHEMBL_ACT_18488163
P35383	5.9	EC50	1260	nM	CHEMBL_ACT_2918172
P35383	5.82	IC50	1510	nM	CHEMBL_ACT_2918158
P2RY2	5.68	EC50	2090	nM	CHEMBL_ACT_2513426
P2RY4	5.6	EC50	2500	nM	CHEMBL_ACT_38858
O35811	5.58	EC50	2600	nM	CHEMBL_ACT_38859
P2RY6	5.22	EC50	6000	nM	CHEMBL_ACT_38860
P2RY6	5.22	EC50	6000	nM	CHEMBL_ACT_6163257

Target pathways

Aggregated over 4 target gene(s): P2RY2, P2RY4, P2RY6, P2RY11.

Top Reactome pathways

6 total, by targets touching each:

Pathway	Targets	Genes
P2Y receptors	4	P2RY11, P2RY2, P2RY4, P2RY6
G alpha (q) signalling events	3	P2RY11, P2RY2, P2RY6
G alpha (s) signalling events	1	P2RY11
G alpha (i) signalling events	1	P2RY4
Surfactant metabolism	1	P2RY2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	1	P2RY2

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	4
phospholipase C-activating G protein-coupled receptor signaling pathway	4
G protein-coupled purinergic nucleotide receptor signaling pathway	4
signal transduction	4
cellular response to ATP	3
transepithelial chloride transport	2
cellular response to prostaglandin E stimulus	2
intracellular monoatomic ion homeostasis	1
positive regulation of mucus secretion	1
blood vessel diameter maintenance	1
positive regulation of cytosolic calcium ion concentration	1
phagocytosis	1
positive regulation of inositol trisphosphate biosynthetic process	1
positive regulation of release of sequestered calcium ion into cytosol	1
positive regulation of ERK1 and ERK2 cascade	1

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
lung neoplasm	3	MONDO:0021117	MONDO:0008903
interstitial lung disease	2	MONDO:0015925	EFO:0004244

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00008255	PHASE2	COMPLETED	INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer
NCT03738943	EARLY_PHASE1	COMPLETED	Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults
NCT00033527	Not specified	UNKNOWN	INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

9 molecules share ≥1 primary target. Top 9 by shared-target count:

Molecule	Source	Status	Shared targets
ADENOSINE	ChEMBL + PubChem	Phase 4 (approved)	P2RY11, P2RY2, P2RY4
DIQUAFOSOL	ChEMBL	Phase 4 (approved)	P2RY2, P2RY4, P2RY6
DIQUAFOSOL TETRASODIUM	ChEMBL	Phase 4 (approved)	P2RY2, P2RY4, P2RY6
DENUFOSOL	ChEMBL	Phase 3	P2RY2, P2RY4, P2RY6
SURAMIN	ChEMBL	Phase 3	P2RY11, P2RY2, P2RY6
ADENOSINE TRIPHOSPHATE	ChEMBL	Phase 2	P2RY11, P2RY2, P2RY4
DENUFOSOL TETRASODIUM	ChEMBL	Phase 3	P2RY2, P2RY4
Carbachol	PubChem	Approved	P2RY2
Indomethacin	PubChem	Approved	P2RY2